Literature DB >> 19616411

Poor outcome in chronic schizophrenia is associated with progressive loss of volume of the putamen.

Serge A Mitelman1, Emily L Canfield, King-Wai Chu, Adam M Brickman, Lina Shihabuddin, Erin A Hazlett, Monte S Buchsbaum.   

Abstract

BACKGROUND: We have previously demonstrated that putaminal but not caudate volumes are associated with poor outcome in patients with chronic schizophrenia. Present longitudinal study was designed to investigate progressive differences in striatal volumes among chronic schizophrenia patients with different outcomes and healthy subjects.
METHODS: Structural MRI scans were acquired at baseline and at follow-up four years later to evaluate volumetric changes in 26 poor-outcome schizophrenia patients, 23 good-outcome patients and 16 healthy subjects.
RESULTS: Schizophrenia patients with different outcomes entered the study with similar volumes of the caudate nucleus and putamen. The rate of decline in volumes of the putamen was greater in patients with poor outcome than in the good-outcome group, so that their putaminal but not caudate volumes were significantly smaller at the time of follow-up. There were no differences in baseline and follow-up volumes of the putamen or in the rate of their progression among patients with schizophrenia and healthy comparison subjects. The caudate volumes were lower in schizophrenia patients than healthy subjects at baseline and follow-up, but showed no differential patterns of progression between the groups.
CONCLUSIONS: Volumes of the putamen may represent a longitudinal marker of treatment responsiveness and outcome in patients with chronic schizophrenia.

Entities:  

Mesh:

Year:  2009        PMID: 19616411      PMCID: PMC2763420          DOI: 10.1016/j.schres.2009.06.022

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  30 in total

1.  Volumetric MRI measurement of caudate nuclei in antipsychotic-naive patients suffering from a first episode of psychosis.

Authors:  Sitra Tauscher-Wisniewski; Johannes Tauscher; Bruce K Christensen; David J Mikulis; Robert B Zipursky
Journal:  J Psychiatr Res       Date:  2004-11-23       Impact factor: 4.791

2.  Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients.

Authors:  P D Harvey; K M Putnam; M Davidson; R S Kahn; P Powchik; R McQueeney; R S Keefe; K L Davis
Journal:  Psychiatry Res       Date:  1991-09       Impact factor: 3.222

3.  Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics.

Authors:  P W Corson; P Nopoulos; D D Miller; S Arndt; N C Andreasen
Journal:  Am J Psychiatry       Date:  1999-08       Impact factor: 18.112

4.  Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine.

Authors:  M H Chakos; J A Lieberman; J Alvir; R Bilder; M Ashtari
Journal:  Lancet       Date:  1995-02-18       Impact factor: 79.321

5.  Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs.

Authors:  M H Chakos; J A Lieberman; R M Bilder; M Borenstein; G Lerner; B Bogerts; H Wu; B Kinon; M Ashtari
Journal:  Am J Psychiatry       Date:  1994-10       Impact factor: 18.112

6.  Progressive deformation of deep brain nuclei and hippocampal-amygdala formation in schizophrenia.

Authors:  Lei Wang; Daniel Mamah; Michael P Harms; Meghana Karnik; Joseph L Price; Mokhtar H Gado; Paul A Thompson; Deanna M Barch; Michael I Miller; John G Csernansky
Journal:  Biol Psychiatry       Date:  2008-09-23       Impact factor: 13.382

7.  Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.

Authors:  Donna J Lang; Lili C Kopala; Robert A Vandorpe; Qing Rui; Geoffrey N Smith; Vina M Goghari; Jocelyne S Lapointe; William G Honer
Journal:  Am J Psychiatry       Date:  2004-10       Impact factor: 18.112

8.  Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia.

Authors:  Gaku Okugawa; Kenji Nobuhara; Katsunori Takase; Yukiko Saito; Masafumi Yoshimura; Toshihiko Kinoshita
Journal:  Neuropsychobiology       Date:  2007-06-08       Impact factor: 2.328

Review 9.  Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings.

Authors:  S Navari; P Dazzan
Journal:  Psychol Med       Date:  2009-04-02       Impact factor: 7.723

10.  [Not Available].

Authors:  Serge A Mitelman; Emily L Canfield; Randall E Newmark; Adam M Brickman; Yuliya Torosjan; King-Wai Chu; Erin A Hazlett; M Mehmet Haznedar; Lina Shihabuddin; Monte S Buchsbaum
Journal:  Open Neuroimag J       Date:  2009-05-20
View more
  21 in total

1.  Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia.

Authors:  Philip R Szeszko; Katherine L Narr; Owen R Phillips; Joanne McCormack; Serge Sevy; Handan Gunduz-Bruce; John M Kane; Robert M Bilder; Delbert G Robinson
Journal:  Schizophr Bull       Date:  2010-11-17       Impact factor: 9.306

2.  The course of neuropsychological performance and functional capacity in older patients with schizophrenia: influences of previous history of long-term institutional stay.

Authors:  Philip D Harvey; Abraham Reichenberg; Christopher R Bowie; Thomas L Patterson; Robert K Heaton
Journal:  Biol Psychiatry       Date:  2010-03-03       Impact factor: 13.382

3.  Intrinsic Connectivity of the Globus Pallidus: An Uncharted Marker of Functional Prognosis in People With First-Episode Schizophrenia.

Authors:  Goda Tarcijonas; William Foran; Gretchen L Haas; Beatriz Luna; Deepak K Sarpal
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

4.  Using longitudinal imaging to map the 'relapse signature' of schizophrenia and other psychoses.

Authors:  V L Cropley; C Pantelis
Journal:  Epidemiol Psychiatr Sci       Date:  2014-05-22       Impact factor: 6.892

5.  Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics.

Authors:  Vicente Molina; Carmen Martín; Alejandro Ballesteros; Alba G Seco de Herrera; Juan Antonio Hernández-Tamames
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-12-30       Impact factor: 5.270

6.  Schizophrenia severity, social functioning and hippocampal neuroanatomy: three-dimensional mapping study.

Authors:  P Brambilla; C Perlini; P Rajagopalan; P Saharan; G Rambaldelli; M Bellani; N Dusi; R Cerini; R Pozzi Mucelli; M Tansella; P M Thompson
Journal:  Br J Psychiatry       Date:  2013-01       Impact factor: 9.319

Review 7.  White matter development in the early stages of psychosis.

Authors:  Bart D Peters; Katherine H Karlsgodt
Journal:  Schizophr Res       Date:  2014-06-02       Impact factor: 4.939

8.  Amygdala volume is reduced in early course schizophrenia.

Authors:  Alyson M Rich; Youngsun T Cho; Yanqing Tang; Aleksandar Savic; John H Krystal; Fei Wang; Ke Xu; Alan Anticevic
Journal:  Psychiatry Res Neuroimaging       Date:  2016-02-12       Impact factor: 2.376

Review 9.  Genetic and Neuroimaging Features of Personality Disorders: State of the Art.

Authors:  Guorong Ma; Hongying Fan; Chanchan Shen; Wei Wang
Journal:  Neurosci Bull       Date:  2016-04-01       Impact factor: 5.203

Review 10.  Schizotypal personality disorder: a current review.

Authors:  Daniel R Rosell; Shira E Futterman; Antonia McMaster; Larry J Siever
Journal:  Curr Psychiatry Rep       Date:  2014-07       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.